13 / 38
Favors SoC
Subgroup
Overall (n=556)
Log Rank (primary)
Cox PH
Sex
Male (n=206)
Female (n=350)
Age at screening
<65 (n=298)
≥65 (n=258)
Race
Asian (n=347)
Non-Asian (n=209)
Smoking history
Yes (n=199)
No (n=357)
CNS metastases
Yes (n=116)
No (n=440)
WHO performance status
0 (n=228)
1 (n=327)
EGFR mutation at randomisation
#
Exon 19 deletion (n=349)
L858R (n=207)
EGFR mutation by ctDNA
ǂ
Positive (n=359)
Negative (n=124)
Centrally confirmed EGFR mutation
§
Positive (n=500)
Negative (n=6)
¶
CNS, central nervous system; ctDNA, circulating tumour DNA; EGFR, epidermal growth factor receptor; PFS, progression-free survival; SoC, standard-of-care; WHO, World Health Organization
Flaura Subgroup Analysis
0.1
0.2 0.3 0.4 0.6 0.8
Hazard ratio
(95% confidence interval)
0.46 (0.37, 0.57)
0.46 (0.37, 0.57)
0.58 (0.41, 0.82)
0.40 (0.30, 0.52)
0.44 (0.33, 0.58)
0.49 (0.35, 0.67)
0.55 (0.42, 0.72)
0.34 (0.23, 0.48)
0.48 (0.34, 0.68)
0.45 (0.34, 0.59)
0.47 (0.30, 0.74)
0.46 (0.36, 0.59)
0.39 (0.27, 0.56)
0.50 (0.38, 0.66)
0.43 (0.32, 0.56)
0.51 (0.36, 0.71)
0.44 (0.34, 0.57)
0.48 (0.28, 0.80)
0.43 (0.34, 0.54)
NC (NC, NC)
2.0
PFS hazard ratio and 95% confidence interval
1.0
Favors osimertinib
10.0
Ramalingam et al ESMO 2017 #LBA2; Soria NEJM 2017